AIDS Treatment News
Table of Contents, August 23, 2004

• Chronically Depressed Women With HIV Almost Twice as Likely as Others to Die From AIDS-Related Causes; Those With Mental-Health Services Had Half the Death Rate of Those Without
  New study strongly correlates mental state with HIV disease outcome, and shows the importance of mental-health services.

• Cambodia Stops Important Tenofovir Prevention Trial
  A study that could open the door to pharmacological HIV prevention until a vaccine is available was stopped in Cambodia, after sex workers objected to lack of health insurance after the trial.

• Hepatitis Coinfection: Two Major Studies Published
  Two large trials showing successful treatment of hepatitis C in persons with HIV were published in the New England Journal of Medicine.
  Advertisement

• FDA Approves Two Combination Pills, Epzicom and Truvada; Comment on Commercial Race to Once-a-Day Nucleosides
  Two combinations of currently available drugs, dosed for once-daily use, were approved by the FDA. We are concerned about too fast a rush to once-a-day.

• Smarter Clinical Trials for Faster Drug Development
  New studies are using modern technology early, to get important dosing, safety and efficacy information about a new drug, starting with the first volunteer who takes it.

• Retroviruses Conference Date Set
  The 2005 Retroviruses conference will be February 22-25 in Boston.

• HIV Treatment and Immunology Research: Current Ideas
  Here are some leading scientific ideas for developing new kinds of HIV treatments.

ISSN # 1052-4207

Copyright 2004 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.